Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HER2-negative Breast Cancer × liposomal doxorubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 33 Ovarian Neoplasms 23 Multiple Myeloma 13 Neoplasms 9 Triple Negative Breast Neoplasms 8 Lymphoma, Large B-Cell, Diffuse 7 Lymphoma 7 Lymphoma, Non-Hodgkin 6 Hodgkin Disease 6 Sarcoma 5 Recurrence 5 Neoplasm Metastasis 5 Carcinoma, Ovarian Epithelial 5 Fallopian Tube Neoplasms 4 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Burkitt Lymphoma 3 Uterine Cervical Neoplasms 2 Mesothelioma, Malignant 2 Lymphoma, Mantle-Cell 2 Lymphoma, Follicular 2 Lung Neoplasms 2 Liver Neoplasms 2 Kidney Neoplasms 2 Disease Progression 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Kaposi 1 Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma 1

Interventions

eribulin 2 Vinorelbine 2 trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 pamiparib 1 liposomal doxorubicin 1 camrelizumab 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡